HEPATIC IMPAIRMENT MEASURED BY QUANTITATIVE TESTS OF LIVER FUNCTION (QLFTS) PREDICTS CLINICAL OUTCOME IN PATIENTS WITH ADVANCED FIBROSIS: RESULTS FROM THE HEPATITIS C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS (HALT-C) TRIAL

被引：0
|
作者：
Everson, Gregory T. [1 ]
Hoefs, John C. [2 ]
Shiffman, Mitchell L. [3 ]
Morgan, Timothy R. [2 ]
Sterling, Richard K. [3 ]
Curto, Teresa M. [5 ]
Wagner, David [4 ]
Wright, Elizabeth C. [6 ]
Everhart, James E. [6 ]
机构：
[1] Univ Colorado, Transplant Ctr & Hepatol, Aurora, CO USA
[2] Univ Calif Irvine, Div Gastroenterol & Hepatol, Irvine, CA USA
[3] VCU, Sect Hepatol, Richmond, VA USA
[4] Metab Solut, Nashua, NH USA
[5] New England Res Inst, Watertown, MA 02172 USA
[6] NIDDK, Bethesda, MD USA
来源：
HEPATOLOGY | 2009年 / 50卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1627
引用
收藏
页码：1057A / 1058A
页数：2
相关论文
共 50 条
  • [31] Weight-Related Effects on Disease Progression in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial
    Everhart, James E.
    Lok, Anna S.
    Kim, Hae-Young
    Morgan, Timothy R.
    Lindsay, Karen L.
    Chung, Raymond T.
    Bonkovsky, Herbert L.
    Ghany, Marc G.
    GASTROENTEROLOGY, 2009, 137 (02) : 549 - 557
  • [32] Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for hepatitis C virus infection
    Ogawa, Eiichi
    Kawano, Akira
    Ooho, Aritsune
    Furusyo, Norihiro
    Satoh, Takeaki
    Takahashi, Kazuhiro
    Kajiwara, Eiji
    Dohmen, Kazufumi
    Nakamuta, Makoto
    Azuma, Koichi
    Koyanagi, Toshimasa
    Yamashita, Nobuyuki
    Yanagita, Kimihiko
    Ichiki, Yasunori
    Kuniyoshi, Masami
    Yamashita, Naoki
    Morita, Chie
    Sugimoto, Rie
    Kato, Masaki
    Shimoda, Shinji
    Nomura, Hideyuki
    Hayashi, Jun
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (02) : 371 - 377
  • [33] Serum alpha-fetoprotein (AFP) levels in patients with advanced hepatitis C-associated liver disease without hepatocellular carcinoma: Results from the HALT-C trial.
    Di Bisceglie, AM
    Dienstag, J
    Bonkovsky, H
    Sterling, R
    Chung, R
    Everhart, J
    Wright, E
    HEPATOLOGY, 2003, 38 (04) : 434A - 434A
  • [34] Short and long-term evaluation of liver fibrosis and outcomes in patients with chronic hepatitis C after INF-free antiviral treatment
    Stasi, Cristina
    Sadalla, Sinan
    Carradori, Eleonora
    Monti, Monica
    Petraccia, Luisa
    Madia, Francesco
    Gragnani, Laura
    Zignego, Anna Linda
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E202 - E203
  • [35] Predicting Clinical Outcomes Using Baseline and Follow-Up Laboratory Data from the Hepatitis C Long-Term Treatment Against Cirrhosis Trial
    Ghany, Marc G.
    Kim, Hae-Young
    Stoddard, Anne
    Wright, Elizabeth C.
    Seeff, Leonard B.
    Lok, Anna S. F.
    HEPATOLOGY, 2011, 54 (05) : 1527 - 1537
  • [36] Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response
    Cordero-Ruiz, Patricia
    Carmona-Soria, Isabel
    Rodriguez-Tellez, Manuel
    Caunedo-Alvarez, Angel
    Quezada-Pacheco, Roberto H.
    Flores-Cucho, Alexander
    Romero-Gomez, Manuel
    Vilches-Arenas, Angel
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 29 (07) : 792 - 799
  • [37] MODEL FOR ENDSTAGE LIVER DISEASE (MELD) SCORE CHANGES DURING HEPATITIS C VIRUS TREATMENT OF PATIENTS WITH CIRRHOSIS PREDICTS LONG-TERM PORTAL HYPERTENSIVE COMPLICATIONS
    Saxena, V.
    Nyberg, L.
    Dasgupta, A.
    Straley, S.
    Catalli, L.
    Nyberg, A.
    Terrault, N.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S628 - S629
  • [38] MODEL FOR ENDSTAGE LIVER DISEASE (MELD) SCORE CHANGES DURING HEPATITIS C VIRUS TREATMENT OF PATIENTS WITH CIRRHOSIS PREDICTS LONG-TERM PORTAL HYPERTENSIVE COMPLICATIONS
    Saxena, V.
    Nyberg, L.
    Dasgupta, A.
    Straley, S.
    Catalli, L.
    Nyberg, A.
    Terrault, N.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S627 - S628
  • [39] Variants in Interferon-Alpha Pathway Genes and Response to Pegylated Interferon-Alpha2a Plus Ribavirin for Treatment of Chronic Hepatitis C Virus Infection in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial
    Welzel, Tania Mara
    Morgan, Timothy R.
    Bonkovsky, Herbert L.
    Naishadham, Deepa
    Pfeiffer, Ruth M.
    Wright, Elizabeth C.
    Hutchinson, Amy A.
    Crenshaw, Andrew T.
    Bashirova, Arman
    Carrington, Mary
    Dotrang, Myhanh
    Sterling, Richard K.
    Lindsay, Karen L.
    Fontana, Robert J.
    Lee, William M.
    Di Bisceglie, Adrian M.
    Ghany, Marc G.
    Gretch, David R.
    Chanock, Stephen J.
    Chung, Raymond T.
    O'Brien, Thomas R.
    HEPATOLOGY, 2009, 49 (06) : 1847 - 1858
  • [40] Clinical utility of alpha fetoprotein (AFP) L3 and des-gamma carboxy prothrombin (DCP) in patients (pts) with hepatitis C (HCV) and advanced fibrosis at risk for hepatocellular carcinoma (HCC): Results from the lead in phase of the HALT-C trial.
    Sterling, RK
    Lok, AS
    Seeff, LB
    Hoefs, JC
    Wright, EC
    GASTROENTEROLOGY, 2005, 128 (04) : A762 - A762
12345